PCL102H1 Lecture Notes - Lecture 15: Tachykinin Receptor 1, Drug Discovery, Substance P
27 Apr 2016
School
Department
Course
Professor
Document Summary
The only way to be confident that a protein is a suitable target for a therapeutic intervention is in retrospect after drug is developed. Many companies have developed highly potent nk1 receptor antagonists, but no effective drug. Good clinical science cannot accurately predict outcome of clinical trials: business/structural. New drug targets pursued by many companies in parallel, increasing overall chance of success. However, economic cost of parallel in clinical trials is greater under conditions of parallel duplication of studies. Chemical probes increase productivity of basic research and facilitate enhanced target validation. Form public-private partnerships to link chemistry resource in industry with biological capabilities in academia. Create transparency by funding the project through intermediary organization, with oversight from independent board of scientists. Pre-competitive chemicals available to all without restriction on use. Generate chemical probes for pioneer targets targets where biological understanding is poor, and clinical validation is lacking. Mission determine 3d structures of human protein structures of medical relevance.
